Treats venous thrombosis and its extension, pulmonary embolism (PE). ANDA 40616, held by Pliva. Warfarin Sodium.
As of Nov 16, 2026, ANDA 40616 (Warfarin Sodium), held by Pliva, was first approved by FDA on Jul 5, 2006, with 7 approved supplements and 0 published complete response letters.
Warfarin sodium tablets are indicated for: Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (PE). Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (AF) and/or cardiac valve replacement. Reduction in the risk of death, recurrent myocardial infarction (MI), and thromboembolic events such as stroke or systemic embolization after myocardial infarction. Limitations of Use Warfarin sodium tablets have no direct effect on an established thrombus, nor does it reverse ischemic tissue damage.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 5, 2006 | Original application | Approved | None posted |
| Warfarin Sodium2MG · tablet;oral | Warfarin Sodium | Rx |
| Warfarin Sodium2.5MG · tablet;oral | Warfarin Sodium | Rx |
| Warfarin Sodium3MG · tablet;oral | Warfarin Sodium | Rx |
| Warfarin Sodium4MG · tablet;oral | Warfarin Sodium | Rx |
| Warfarin Sodium5MG · tablet;oral | Warfarin Sodium | Rx |
| Warfarin Sodium6MG · tablet;oral | Warfarin Sodium | Rx |
| Warfarin Sodium7.5MG · tablet;oral | Warfarin Sodium | Rx |
| Warfarin Sodium10MG · tablet;oral | Warfarin Sodium | Rx |
| Warfarin Sodium1MG · tablet;oral | Warfarin Sodium | Rx |
| Jul 2, 2025 | Supplement 21Labeling · Standard review | Approved | None posted |
| Sep 5, 2018 | Supplement 9Labeling · Standard review | Approved | None posted |
| Sep 5, 2018 | Supplement 12Labeling · Standard review | Approved | None posted |
| Sep 5, 2018 | Supplement 14Labeling · Standard review | Approved | None posted |
| Sep 5, 2018 | Supplement 15Labeling · Standard review | Approved | None posted |
| Sep 5, 2018 | Supplement 16Manufacturing | Approved | None posted |
| Jul 11, 2007 | Supplement 2Labeling | Approved | None posted |
| Jul 5, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters